Academic Journal
Shengqingjiangzhuo Capsules Alleviates Renal Fibrosis by Targeting Glomerular Endothelial Cells Exosome miR-31-5p/HO-1 to Suppress Tubular Epithelial Cells Ferroptosis.
| Τίτλος: | Shengqingjiangzhuo Capsules Alleviates Renal Fibrosis by Targeting Glomerular Endothelial Cells Exosome miR-31-5p/HO-1 to Suppress Tubular Epithelial Cells Ferroptosis. |
|---|---|
| Συγγραφείς: | Pan F; Department of Nephrology, Ningxia Hui Autonomous Region Hospital of Traditional Chinese Medicine, Ningxia Hui Autonomous Region Academy of Traditional Chinese Medicine, Yinchuan, Ningxia, China., Lu J; Department of Nephrology, Ningxia Hui Autonomous Region Hospital of Traditional Chinese Medicine, Ningxia Hui Autonomous Region Academy of Traditional Chinese Medicine, Yinchuan, Ningxia, China., Ye G; Department of Nephrology, Ningxia Hui Autonomous Region Hospital of Traditional Chinese Medicine, Ningxia Hui Autonomous Region Academy of Traditional Chinese Medicine, Yinchuan, Ningxia, China., Zhu H; College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia, China., Ma H; Department of Nephrology, Ningxia Hui Autonomous Region Hospital of Traditional Chinese Medicine, Ningxia Hui Autonomous Region Academy of Traditional Chinese Medicine, Yinchuan, Ningxia, China., Li J; College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia, China., Yang X; College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia, China., Yang H; Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.; National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.; Tianjin University of Traditional Chinese Medicine, Tianjin, China., Tong A; Department of Nephrology, Ningxia Hui Autonomous Region Hospital of Traditional Chinese Medicine, Ningxia Hui Autonomous Region Academy of Traditional Chinese Medicine, Yinchuan, Ningxia, China. |
| Πηγή: | Clinical and experimental pharmacology & physiology [Clin Exp Pharmacol Physiol] 2026 Sep; Vol. 53 (9), pp. e70151. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0425076 Publication Model: Print Cited Medium: Internet ISSN: 1440-1681 (Electronic) Linking ISSN: 03051870 NLM ISO Abbreviation: Clin Exp Pharmacol Physiol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford, England : Wiley-Blackwell Original Publication: Oxford, Blackwell Scientific Publications. |
| Ιατρικοί όροι (MeSH): | MicroRNAs*/genetics , MicroRNAs*/metabolism , Exosomes*/drug effects , Exosomes*/metabolism , Exosomes*/genetics , Drugs, Chinese Herbal*/pharmacology , Drugs, Chinese Herbal*/therapeutic use , Ferroptosis*/drug effects , Epithelial Cells*/drug effects , Epithelial Cells*/pathology , Epithelial Cells*/metabolism , Heme Oxygenase-1*/metabolism , Heme Oxygenase-1*/genetics , Kidney Tubules*/pathology , Kidney Tubules*/drug effects , Endothelial Cells*/drug effects , Endothelial Cells*/metabolism , Endothelial Cells*/pathology , Membrane Proteins*/metabolism , Membrane Proteins*/genetics, Animals ; Fibrosis ; Mice ; Male ; Capsules ; Mice, Inbred C57BL |
| Περίληψη: | Objective: Chronic renal failure (CRF) represents the advanced stage of chronic kidney disease, for which no specific pharmacological treatments are currently available. Traditional Chinese medicine has demonstrated notable efficacy in managing CRF. Shengqingjiangzhuo capsules (SQJZ capsules), a traditional Chinese medicinal formulation, are employed clinically in the treatment of CRF. However, the precise mechanisms underlying its therapeutic effects remain insufficiently understood. Methods: The SQJZ capsule's chemical components were identified using UPLC-Q-Exactive-Orbitrap-MS. TGFβ1-induced GECs and adenine-induced CRF models in mice were developed. Exosome miRNA sequencing, quantitative polymerase chain reaction (qPCR), Western blot and dual-luciferase reporter assays explored the interaction between miR-31-5p and HO-1, and their effects on ferroptosis markers (ROS, GSH, MDA, Fe2+, SLC7A11, GCLC), mitochondrial membrane potential and fibrosis markers α-SMA and collagen I. Results: This study is the first to employ UPLC-Q-Exactive-Orbitrap-MS technology to analyse SQJZ capsules, identifying 82 active components. It indicates that TGF-β1-stimulated GECs-derived exosomes increase miR-31-5p in TECs, causing HO-1 inhibition and ferroptosis. The active drug in SQJZ capsules serum counteracts these effects, suggesting anti-ferroptosis and anti-fibrosis properties and improving renal function in cell and CRF animal models. Overall, SQJZ capsules reduce renal fibrosis by modulating the miR-31-5p/HO-1 axis and inhibiting ferroptosis in TECs. Conclusion: SQJZ capsules is associated with amelioration of renal fibrosis by suppressing GECs-derived exosomal miR-31-5p, which derepresses HO-1 expression in TECs, thereby inhibiting ferroptosis and subsequent renal fibrosis. (© 2026 John Wiley & Sons Australia, Ltd.) |
| References: | Bioengineered. 2021 Dec;12(1):6538-6558. (PMID: 34528858) Ren Fail. 2025 Dec;47(1):2539936. (PMID: 40745008) Free Radic Biol Med. 2025 Aug 1;235:162-175. (PMID: 40311785) Biomedicines. 2024 Nov 28;12(12):. (PMID: 39767635) Kidney Int. 2012 Apr;81(7):617-27. (PMID: 22237749) Int J Mol Sci. 2020 Sep 07;21(18):. (PMID: 32906849) Genes (Basel). 2022 Nov 24;13(12):. (PMID: 36553468) Front Immunol. 2026 Feb 04;17:1737751. (PMID: 41716407) Acta Pharmacol Sin. 2023 Dec;44(12):2455-2468. (PMID: 37596398) Cell Death Differ. 2020 Jan;27(1):210-226. (PMID: 31097789) Front Nutr. 2021 Nov 24;8:778998. (PMID: 34901124) J Vis Exp. 2022 Sep 13;(187):. (PMID: 36190268) J Extracell Vesicles. 2022 Mar;11(3):e12203. (PMID: 35312232) Mol Ther Nucleic Acids. 2022 Jan 10;27:838-853. (PMID: 35141045) Comput Biol Chem. 2026 Feb;120(Pt 1):108750. (PMID: 41270547) Int Immunopharmacol. 2023 Jan;114:109429. (PMID: 36459921) Int J Mol Sci. 2022 Mar 30;23(7):. (PMID: 35409151) Ann Thorac Surg. 2021 Mar;111(3):828-835. (PMID: 32822666) BMC Complement Altern Med. 2015 Sep 08;15:316. (PMID: 26351087) JCI Insight. 2019 Nov 14;4(22):. (PMID: 31613798) Yi Chuan. 2020 Nov 20;42(11):1062-1072. (PMID: 33229313) Cell Death Dis. 2018 Nov 13;9(11):1126. (PMID: 30425237) Int J Mol Sci. 2019 Apr 23;20(8):. (PMID: 31018516) JCI Insight. 2025 Dec 17;11(3):. (PMID: 41410530) Phytomedicine. 2025 Jul;142:156762. (PMID: 40305973) J Am Soc Nephrol. 2013 Feb;24(3):385-92. (PMID: 23274427) Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):907-11. (PMID: 20332265) Int J Biol Sci. 2021 Sep 21;17(14):4021-4033. (PMID: 34671216) Science. 2020 Feb 7;367(6478):. (PMID: 32029601) Int J Mol Sci. 2023 Oct 24;24(21):. (PMID: 37958504) Cytokine Growth Factor Rev. 2022 Apr;64:33-45. (PMID: 35219587) Acta Biochim Biophys Sin (Shanghai). 2024 May 28;56(9):1311-1322. (PMID: 38808395) Naunyn Schmiedebergs Arch Pharmacol. 2026 Feb;399(3):4247-4265. (PMID: 41105249) Int J Mol Sci. 2021 Jan 02;22(1):. (PMID: 33401711) Cell Prolif. 2020 Mar;53(3):e12763. (PMID: 31925859) Vet Res. 2023 Jun 28;54(1):52. (PMID: 37381058) Ren Fail. 2024 Dec;46(1):2336128. (PMID: 38575340) Front Cell Dev Biol. 2021 Jun 24;9:675617. (PMID: 34249928) Biochemistry (Mosc). 2023 Oct;88(10):1622-1644. (PMID: 38105029) Gen Physiol Biophys. 2023 Mar;42(2):149-158. (PMID: 36896944) Biomolecules. 2021 Apr 16;11(4):. (PMID: 33923744) FASEB J. 2020 Jan;34(1):410-431. (PMID: 31914684) Methods Mol Biol. 2024;2835:181-213. (PMID: 39105917) J Extracell Vesicles. 2018 Nov 23;7(1):1535750. (PMID: 30637094) Cell Death Dis. 2021 Jan 11;12(1):65. (PMID: 33431801) J Cell Mol Med. 2019 Feb;23(2):731-739. (PMID: 30585399) Free Radic Biol Med. 2025 Sep;237:131-146. (PMID: 40456495) Genesis. 2024 Feb;62(1):e23529. (PMID: 37345818) J Adv Res. 2020 Jul 22;28:231-243. (PMID: 33364059) Redox Biol. 2016 Apr;7:58-67. (PMID: 26654978) Methods Mol Biol. 2023;2576:385-393. (PMID: 36152204) J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117189. (PMID: 37716490) Cell Death Dis. 2020 Feb 3;11(2):88. (PMID: 32015325) Acta Biochim Pol. 2018 Nov 27;65(4):613-620. (PMID: 30481230) BMC Nephrol. 2018 Jul 31;19(1):190. (PMID: 30064367) J Ethnopharmacol. 2025 Jan 30;337(Pt 1):118812. (PMID: 39260710) Signal Transduct Target Ther. 2023 Mar 27;8(1):121. (PMID: 36967385) J Pharm Anal. 2024 Aug;14(8):100933. (PMID: 39247486) Cancers (Basel). 2023 Feb 09;15(4):. (PMID: 36831463) Heliyon. 2024 Jan 26;10(3):e25131. (PMID: 39668858) Biol Open. 2016 Apr 15;5(4):484-91. (PMID: 27010029) |
| Grant Information: | 2022AAC05053 Natural Science Foundation of Ningxia Province; Zyyzdxk-2023210 high-level key discipline construction project of National Administration of Traditional Chinese Medicine of China; 2022BEG02036 the key Research and Development Program of Ningxia Hui Autonomous Region |
| Contributed Indexing: | Keywords: Shengqingjiangzhuo capsules; endothelial cells; epithelial cells; exosomes; fibrosis |
| Substance Nomenclature: | 0 (MicroRNAs) 0 (Drugs, Chinese Herbal) 0 (Capsules) EC 1.14.14.18 (Heme Oxygenase-1) 0 (Membrane Proteins) EC 1.14.14.18 (Hmox1 protein, mouse) |
| Entry Date(s): | Date Created: 20260828 Date Completed: 20260828 Latest Revision: 20260830 |
| Update Code: | 20260830 |
| PubMed Central ID: | PMC13522403 |
| DOI: | 10.1111/1440-1681.70151 |
| PMID: | 42661282 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1440-1681 |
|---|---|
| DOI: | 10.1111/1440-1681.70151 |